Video Experimental Relacionado
Updated: Jun 14, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.1K
Un ensayo clínico aleatorizado de dosis bajas de triple píldora frente a protocolos de atención estándar para el
Dike B Ojji1,2, Abdul Salam3,4,5, Mahmoud U Sani6
1Department of Internal Medicine, University of Abuja, Abuja, Nigeria.
JAMA
|August 31, 2024
Resumen
Un nuevo régimen de dosis baja de triple píldora redujo efectivamente la presión arterial en adultos negros africanos con hipertensión no controlada. Este tratamiento demostró un control superior de la presión arterial y una buena tolerabilidad en comparación con el tratamiento estándar.
Área de la Ciencia:
- Medicina cardiovascular
- Farmacología clínica
- Salud pública
Sus antecedentes:
- La hipertensión representa una carga significativa para la salud en el África subsahariana, lo que requiere opciones de tratamiento efectivas y escalables.
- Las estrategias de tratamiento actuales pueden no ser óptimas para la población negra africana, lo que pone de relieve la necesidad de una investigación comparativa de la eficacia.
Objetivo del estudio:
- Evaluar la eficacia y la seguridad de un nuevo protocolo antihipertensivo de dosis baja con píldora triple frente a la atención estándar en adultos negros africanos.
- Para comparar la reducción de la presión arterial y las tasas de control entre los dos brazos de tratamiento.
Principales métodos:
- Se realizó un ensayo multicéntrico aleatorizado, de grupo paralelo y abierto en clínicas de medicina familiar de Nigeria.
- Los participantes con hipertensión no controlada recibieron una combinación triple de dosis bajas (telmisartán, amlodipino, indapamida) o el protocolo estándar de tratamiento de la hipertensión nigeriana.
- El resultado primario fue la reducción de la presión arterial sistólica a los 6 meses; la seguridad se evaluó mediante la interrupción del tratamiento debido a eventos adversos.
Principales resultados:
- El grupo de la triple píldora de dosis baja mostró una reducción significativamente mayor de la presión arterial sistólica en el hogar (31 mm Hg) en comparación con el grupo de atención estándar (26 mm Hg) a los 6 meses.
- El control de la presión arterial en el hogar (< 130/ 80 mm Hg) se logró en el 62% de los participantes en el protocolo de la píldora triple frente al 28% en el tratamiento estándar.
- Ningún participante interrumpió el tratamiento debido a eventos adversos, lo que indica una buena tolerabilidad para el régimen de píldoras triples.
Conclusiones:
- Un protocolo de triple píldora de dosis baja ofrece una reducción y un control superiores de la presión arterial en adultos negros africanos con hipertensión no controlada.
- Este nuevo régimen es bien tolerado y representa una estrategia prometedora y escalable para el manejo de la hipertensión en esta población.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:18Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404